Iron Overload Disorder – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Iron Overload indicates a physical condition resulting in increased total body iron stores, with or without organ dysfunction. In other words, it refers to a cluster of genetic or acquired conditions that result in the extra accumulation of iron in the body. Since excess iron is toxic to the cells, its collection can lead to permanent tissue damage, resulting in organ failure if left untreated for a prolonged period. Iron Overload is caused by an inherited disorder called hereditary hemochromatosis (HH) or is acquired in patients with certain conditions that need frequent blood transfusions. Iron homeostasis depends on a complex feedback mechanism between body iron requirements and intestinal absorption. Humans lack a physiological mechanism for the excretion of excess iron. The hormone hepcidin, a 25-amino acid peptide, is produced mainly in the liver and secreted into the blood and is now recognized as the critical regulator of iron homeostasis. Any disruptions in the regulation of hepcidin are a cause of many disorders related to iron homeostasis. Iron overload syndromes are broadly divided into inherited or Primary iron overload called hereditary hemochromatosis (HH) and Secondary iron overload syndromes. The former is a genetic disorder that causes the body to absorb excessive iron from the diet. The most common subtype of the above is HFE related HH caused by mutations in the human hemochromatosis gene (HFE). The HFE protein regulates the absorption of iron by controlling hepcidin production.

 

The prevalence of primary and secondary iron overload syndromes cases varies from 325 to 385 cases per 100,000 in the USA.

 

The competitive landscape of Iron Overload Disorder includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Iron Overload Disorder across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Iron Overload Disorder Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Iron Overload Disorder – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Deferasirox       Novartis Pharmaceuticals          Phase 2

2          Deferiprone       ApoPharma       Phase 2

3          SP-420 Abfero Pharmaceuticals, Inc      Phase 1

4          SPD602            Shire    Phase 2

5          LJPC-401         La Jolla Pharmaceutical Company          Phase 2

6          apo transferrin  Prothya Biosolutions      Phase 3

7          BBI-001            Bond Biosciences          Phase 1

8          PTG-300           Protagonist Therapeutics, Inc.    Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more